Improving early reperfusion with adjuvant dornase alfa in large vessel ischemic stroke.
An umbrella Bayesian optimized phase 2 trial of dornase alfa (Pulmozyme™) in addition to standard intravenous thrombolysis before endovascular thrombectomy within 4.5 hours of stroke onset
Lead PI: Prof Bruce Campbell
Status: Recruiting
No. of Patients Currently Recruited: No. of Patients Required: 300
Thrombus contains structural components other than fibrin, including DNA from neutrophil extracellular traps (NETS). Dornase alfa can dissolve NETS and accelerates ex vivo lysis of retrieved thrombi from stroke patients when combined with alteplase or tenecteplase. EXTEND-IA DNase will investigate whether reperfusion at initial angiogram is improved by addition of dornase to standard care tenecteplase. Three dornase doses will be tested.
Trial URL:
